文献速递神经肿瘤

鞘内化疗治疗高级别胶质瘤软脑膜病变:一项系统综述

Intrathecal chemotherapy for leptomeningeal disease in high-grade gliomas: a systematic review.
PubMed 文献 · J Neurooncol · 2024-01-31

该系统综述检索1995年1月至2022年9月PubMed与Embase,纳入10项临床研究共68例高级别胶质瘤继发软脑膜病变患者,总结鞘内化疗方案的安全性、生存数据及不良反应,认为总体预后差,需进一步研究以明确如何最大化鞘内化疗的潜在疗效。

要点

  • 68例患者平均诊断年龄44.2岁,胶质母细胞瘤占85.3%(n=58)。
  • 多数患者为复发疾病(n=29,60.4%),鞘内化疗方案包括马磷酰胺、塞替派、FdUrd、甲氨蝶呤和阿糖胞苷。
  • 队列平均无进展生存期7.5个月,总生存期11.7个月;常见不良反应为头痛、恶心、呕吐。

核心结论

  • 高级别胶质瘤继发软脑膜病变仍是不常见并发症且预后差,本综述概述了现有鞘内化疗文献及其治疗方案与总生存特征,需进一步研究以明确如何最大化鞘内化疗作为治疗选择的潜在疗效。

研究设计与样本

  • 遵循PRISMA指南的系统综述,检索PubMed和Embase自1995年1月至2022年9月,纳入诊断为高级别胶质瘤继发软脑膜病变、接受鞘内化疗并提供生存数据的患者,共10项临床研究68例患者。

主要发现

  • 68例患者平均诊断年龄44.2岁,胶质母细胞瘤为最常见类型(n=58,85.3%)。
  • 多数患者为复发疾病(n=29,60.4%)。
  • 鞘内化疗方案包括马磷酰胺、塞替派、5-氟-2'-脱氧尿苷(FdUrd)、甲氨蝶呤(MTX)和阿糖胞苷,但剂量和频率报告不一致。
  • 队列平均无进展生存期(PFS)为7.5个月,总生存期(OS)为11.7个月。
  • 常见不良反应包括头痛、恶心和呕吐,部分病例报告骨髓毒性、弥散性血管内凝血、脑膜炎和胃肠道毒性等较严重并发症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Leptomeningeal disease (LMD) secondary to high grade glioma (HGG), such as glioblastoma (GBM), are characterized by the spread of tumor cells to the leptomeninges which further complicates treatment approaches. Intrathecal (IT) chemotherapy has surfaced as a potential strategy to bypass the blood-brain barrier and address the challenges posed by disseminated disease. Here, we present a review of the safety and efficacy of IT chemotherapy in the treatment of LMD secondary to HGG. METHODS: A systematic review following PRISMA guidelines was conducted searching PubMed and Embase from January 1995 to September 2022 using specified terms related to IT chemotherapy for LMD. Included articles involved patients diagnosed with LMD from HGG, treated with intrathecal chemotherapy, and provided survival data. Data, including demographics, tumor characteristics, treatment, and survival information, were collected and independently extracted. RESULTS: A total of 68 patients across 10 clinical studies were diagnosed with LMD from HGG and included in the review. Among these patients, the average age at diagnosis was 44.2 years. GBM was the most common tumor type (n = 58, 85.3%). A majority of the patients presented with recurrent disease (n = 29, 60.4%). The review encompassed various IT chemotherapy regimens, including mafosfamide, thio-TEPA, 5-fluoro-2'-deoxyuridine (FdUrd), methotrexate (MTX), and cytarabine; however, dosages and frequencies were inconsistently reported. The mean progression-free survival (PFS) and overall survival (OS) for this cohort were 7.5 months and 11.7 months, respectively. Common side effects of IT chemotherapy included headaches, nausea, and vomiting, with more severe complications such as myelotoxicity, disseminated intravascular coagulopathy, meningitis, and gastrointestinal toxicity reported in some cases. CONCLUSION: LMD continues to be an uncommon complication associated with HGG with a poor prognosis. This article provides an overview of the presently available literature on IT chemotherapy for LMD secondary to HGG, and their respective treatment protocols with overall survival attributes. Additional research is warranted to ascertain how to maximize the potential efficacy of IT chemotherapy as a treatment option.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Singh E, Gurses ME, Costello MC, et al. Intrathecal chemotherapy for leptomeningeal disease in high-grade gliomas: a systematic review. J Neurooncol. 2024. PMID: 38294637. doi:10.1007/s11060-024-04582-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。